JP2025510368A - 不安の処置 - Google Patents
不安の処置 Download PDFInfo
- Publication number
- JP2025510368A JP2025510368A JP2024557758A JP2024557758A JP2025510368A JP 2025510368 A JP2025510368 A JP 2025510368A JP 2024557758 A JP2024557758 A JP 2024557758A JP 2024557758 A JP2024557758 A JP 2024557758A JP 2025510368 A JP2025510368 A JP 2025510368A
- Authority
- JP
- Japan
- Prior art keywords
- dmt
- meo
- pharma
- acceptable salt
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22000086 | 2022-03-27 | ||
| EP22000083 | 2022-03-27 | ||
| EP22000083.0 | 2022-03-27 | ||
| EP22000086.3 | 2022-03-27 | ||
| EP23153995.8 | 2023-01-30 | ||
| EP23153939.6 | 2023-01-30 | ||
| EP23153995 | 2023-01-30 | ||
| EP23153939 | 2023-01-30 | ||
| PCT/EP2023/057857 WO2023186816A1 (en) | 2022-03-27 | 2023-03-27 | Treatment of anxiety |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510368A true JP2025510368A (ja) | 2025-04-14 |
| JP2025510368A5 JP2025510368A5 (enExample) | 2026-04-07 |
Family
ID=86007166
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557758A Pending JP2025510368A (ja) | 2022-03-27 | 2023-03-27 | 不安の処置 |
| JP2024557755A Pending JP2025511081A (ja) | 2022-03-27 | 2023-03-27 | 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ |
| JP2024557204A Pending JP2025512831A (ja) | 2022-03-27 | 2023-03-27 | 認知機能障害の治療 |
| JP2024557759A Pending JP2025510369A (ja) | 2022-03-27 | 2023-03-27 | 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557191A Pending JP2025510912A (ja) | 2022-03-27 | 2023-03-27 | 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557205A Pending JP2025510916A (ja) | 2022-03-27 | 2023-03-27 | 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557755A Pending JP2025511081A (ja) | 2022-03-27 | 2023-03-27 | 睡眠障害の治療における使用のための５－ＭｅＯ－ＤＭＴ |
| JP2024557204A Pending JP2025512831A (ja) | 2022-03-27 | 2023-03-27 | 認知機能障害の治療 |
| JP2024557759A Pending JP2025510369A (ja) | 2022-03-27 | 2023-03-27 | 社会的／情動的引きこもりまたは離隔の処置のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557191A Pending JP2025510912A (ja) | 2022-03-27 | 2023-03-27 | 双極性障害を処置するための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
| JP2024557205A Pending JP2025510916A (ja) | 2022-03-27 | 2023-03-27 | 精神運動遅滞の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US20250205199A1 (enExample) |
| EP (7) | EP4499075A1 (enExample) |
| JP (6) | JP2025510368A (enExample) |
| KR (6) | KR20250005183A (enExample) |
| CN (2) | CN119095595A (enExample) |
| AU (6) | AU2023246679A1 (enExample) |
| CA (6) | CA3255505A1 (enExample) |
| IL (6) | IL315891A (enExample) |
| WO (9) | WO2023186826A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| EP3868364A1 (en) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| GB202306256D0 (en) * | 2023-04-27 | 2023-06-14 | Beckley Psytech Ltd | 5-Methoxy-N,N-Dimethyltryptamine Formulations |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2026078143A1 (en) | 2024-10-09 | 2026-04-16 | GH Research Ireland Limited | Combinations of 5-meo-dmt with antidepressants for treating depression |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
| CA2526478A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
| DE502006008441D1 (de) | 2006-08-01 | 2011-01-13 | Stobi Gmbh & Co Kg | Ventilballon für Inhalatoren |
| US20200147038A1 (en) * | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| HUE066828T2 (hu) | 2019-02-22 | 2024-09-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-Dimetiltriptamin (5-Meo-Dmt) súlyos depressziós rendellenesség kezelésére |
| DK3927338T3 (da) * | 2019-02-22 | 2025-01-06 | Gh Res Ireland Limited | Sammensætninger omfattende 5-methoxy-n,n-dimethyltryptamin (5-meo-dmt) til anvendelse i behandling af mentale lidelser |
| KR20220008824A (ko) * | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| EP3753923A1 (en) * | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| LT4084791T (lt) * | 2020-02-18 | 2025-02-25 | Gilgamesh Pharmaceuticals, Inc. | Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti |
| EP3868364A1 (en) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| US20230157981A1 (en) * | 2020-04-20 | 2023-05-25 | Lobe Sciences Ltd. | Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder |
| IL297861A (en) * | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| BR112022025306A2 (pt) * | 2020-06-12 | 2023-02-28 | Beckley Psytech Ltd | Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina |
| US11406619B2 (en) * | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022189662A1 (en) | 2021-03-12 | 2022-09-15 | Alvarius Pharmaceuticals Ltd. | Compositions and methods for treating addictions comprising 5-meo-dmt |
| WO2023186834A1 (en) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Crystalline hydrobromide salt of 5-meo-dmt |
-
2023
- 2023-03-27 JP JP2024557758A patent/JP2025510368A/ja active Pending
- 2023-03-27 US US18/850,370 patent/US20250205199A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057873 patent/WO2023186826A1/en not_active Ceased
- 2023-03-27 US US18/850,362 patent/US20250241892A1/en active Pending
- 2023-03-27 AU AU2023246679A patent/AU2023246679A1/en active Pending
- 2023-03-27 EP EP23717035.2A patent/EP4499075A1/en active Pending
- 2023-03-27 EP EP23717031.1A patent/EP4499226A1/en active Pending
- 2023-03-27 CA CA3255505A patent/CA3255505A1/en active Pending
- 2023-03-27 CN CN202380030914.XA patent/CN119095595A/zh active Pending
- 2023-03-27 KR KR1020247035762A patent/KR20250005183A/ko active Pending
- 2023-03-27 CA CA3255343A patent/CA3255343A1/en active Pending
- 2023-03-27 EP EP23717042.8A patent/EP4499082A1/en active Pending
- 2023-03-27 CA CA3255348A patent/CA3255348A1/en active Pending
- 2023-03-27 US US18/851,346 patent/US20250241895A1/en active Pending
- 2023-03-27 EP EP23717412.3A patent/EP4499088A1/en active Pending
- 2023-03-27 IL IL315891A patent/IL315891A/en unknown
- 2023-03-27 WO PCT/EP2023/057857 patent/WO2023186816A1/en not_active Ceased
- 2023-03-27 IL IL315902A patent/IL315902A/en unknown
- 2023-03-27 US US18/850,376 patent/US20250241893A1/en active Pending
- 2023-03-27 KR KR1020247035758A patent/KR20250005181A/ko active Pending
- 2023-03-27 WO PCT/EP2023/057877 patent/WO2023186830A1/en not_active Ceased
- 2023-03-27 KR KR1020247035746A patent/KR20250005179A/ko active Pending
- 2023-03-27 JP JP2024557755A patent/JP2025511081A/ja active Pending
- 2023-03-27 KR KR1020247035659A patent/KR20240167879A/ko active Pending
- 2023-03-27 EP EP23717043.6A patent/EP4499083A1/en active Pending
- 2023-03-27 JP JP2024557204A patent/JP2025512831A/ja active Pending
- 2023-03-27 IL IL315898A patent/IL315898A/en unknown
- 2023-03-27 US US18/850,383 patent/US20250205256A1/en not_active Abandoned
- 2023-03-27 JP JP2024557759A patent/JP2025510369A/ja active Pending
- 2023-03-27 WO PCT/EP2023/057876 patent/WO2023186829A1/en not_active Ceased
- 2023-03-27 WO PCT/EP2023/057870 patent/WO2023186823A1/en not_active Ceased
- 2023-03-27 AU AU2023246543A patent/AU2023246543A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057867 patent/WO2023186820A1/en not_active Ceased
- 2023-03-27 CA CA3255629A patent/CA3255629A1/en active Pending
- 2023-03-27 EP EP23717036.0A patent/EP4499076A1/en not_active Withdrawn
- 2023-03-27 US US18/850,348 patent/US20250241891A1/en active Pending
- 2023-03-27 IL IL315897A patent/IL315897A/en unknown
- 2023-03-27 WO PCT/EP2023/057883 patent/WO2023186835A1/en not_active Ceased
- 2023-03-27 KR KR1020247035653A patent/KR20250005170A/ko active Pending
- 2023-03-27 IL IL315896A patent/IL315896A/en unknown
- 2023-03-27 AU AU2023244452A patent/AU2023244452A1/en active Pending
- 2023-03-27 AU AU2023246545A patent/AU2023246545A1/en active Pending
- 2023-03-27 AU AU2023246774A patent/AU2023246774A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057842 patent/WO2023186806A1/en not_active Ceased
- 2023-03-27 CA CA3255648A patent/CA3255648A1/en active Pending
- 2023-03-27 CA CA3255340A patent/CA3255340A1/en active Pending
- 2023-03-27 WO PCT/EP2023/057827 patent/WO2023186797A1/en not_active Ceased
- 2023-03-27 CN CN202380031464.6A patent/CN119053327A/zh active Pending
- 2023-03-27 JP JP2024557191A patent/JP2025510912A/ja active Pending
- 2023-03-27 US US18/851,343 patent/US20250213532A1/en active Pending
- 2023-03-27 EP EP23717033.7A patent/EP4499073A1/en active Pending
- 2023-03-27 KR KR1020247035718A patent/KR20250005176A/ko active Pending
- 2023-03-27 JP JP2024557205A patent/JP2025510916A/ja active Pending
- 2023-03-27 IL IL315899A patent/IL315899A/en unknown
- 2023-03-27 AU AU2023242291A patent/AU2023242291A1/en active Pending
- 2023-09-27 US US18/373,906 patent/US20240108602A1/en active Pending
- 2023-09-27 US US18/373,903 patent/US20240108601A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025512866A (ja) | 不安の治療のための５－メトキシ－ｎ，ｎ－ジメチルトリプタミン | |
| KR20250005179A (ko) | 불안의 치료 | |
| KR20250139377A (ko) | 수유부의 정신 장애 치료에 사용하기 위한 5-메톡시-n,n-다이메틸트립타민 | |
| KR20250138805A (ko) | 정신 장애의 치료 | |
| CN118973570A (zh) | 焦虑的治疗 | |
| JP2025510911A (ja) | 精神障害の治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260327 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260327 |